Skip to content

Autologous PRP Intra Ovarian Infusion to Restore Ovarian Function in Menopausal Women

Investigating Reactivation of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in Menopausal Women

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03916978
Acronym
PRP
Enrollment
100
Registered
2019-04-16
Start date
2019-05-21
Completion date
2028-07-30
Last updated
2026-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amenorrhea, Anovulatory Infertility, Infertility, Female, Menopause

Keywords

Ovarian rejuvenation, Ovarian reactivation; ovulation

Brief summary

Autologous PRP intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve hormonal profile of women in menopause.

Detailed description

This triple-blind Randomized Controlled Trial (RCT) aims to investigate the effectiveness of autologous PRP intra ovarian infusion on reactivating ovarian functionality and on promoting folliculogenesis in regard to menopausal women. PRP is blood plasma prepared from fresh whole blood that has been enriched with platelets. It is collected from peripheral veins and contains several growth factors such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor (TGF) and other cytokines all of which stimulate tissue proliferation and growth. PRP has been employed in several medical conditions in Orthopedics, Dermatology, and Ophthalmology for wound healing. It's efficacy in ovarian rejuvenation and reactivation and endometrial regeneration has not been fully elucidated. This study aims to investigate the effect of autologous PRP intra ovarian infusion on restoring ovarian tissue functionality in menopausal women.

Interventions

BIOLOGICALAutologous PRP intra ovarian infusion

Autologous PRP intra ovarian infusion

BIOLOGICALAutologous PFP intra ovarian infusion

Autologous PFP intra ovarian infusion

Sponsors

Genesis Athens Clinic
Lead SponsorOTHER
National and Kapodistrian University of Athens
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Age between 45-55 years old * Amenorrhea for at least 12 months * Discontinuation of any complementary/adjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment. * Willing to comply with study requirements

Exclusion criteria

* Any pathological disorder related to reproductive system anatomy * Previous POI diagnosis * Abnormal karyotype * Endometriosis * Adenomyosis * Fibroids and adhesions * Infections in reproductive system * Current or previous diagnosis of reproductive system cancer * History of familiar cancer in reproductive system * Severe male factor infertility * Prior referral for PGT * Ovarian inaccessibility * Endocrinological disorders (Hypothalamus-Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome) * BMI\>30 kg/m2 or BMI\<18.5 kg/m2 * Systematic autoimmune disorders

Design outcomes

Primary

MeasureTime frameDescription
Restoration of menstrual cycleThree monthsMenstrual cycle restoration
Serum FSH levelsFollow-up period of three months entailing monthly evaluationSerum FSH levels evaluated monthly for three consecutive months.

Secondary

MeasureTime frameDescription
Serum AMH levelsFollow-up period of three months entailing monthly evaluationSerum AMH levels evaluated monthly for three consecutive months.
Serum estradiol levelsFollow-up period of three months entailing monthly evaluationSerum estradiol levels evaluated monthly for three consecutive months.
Serum LH levelsFollow-up period of three months entailing monthly evaluationSerum LH levels evaluated monthly for three consecutive months.
Serum progesterone levelsFollow-up period of three months entailing monthly evaluationSerum progesterone levels evaluated monthly for three consecutive months.
Antral Follicle CountFollow-up period of three months entailing monthly evaluationAFC evaluated monthly, on day 2 of the menstrual cycle, for three consecutive months.

Countries

Greece

Contacts

CONTACTMara Simopoulou, PhD
marasimopoulou@hotmail.com+306979234100
CONTACTAgni Pantou, MD
agni.pantou@genesisathens.gr+306974447702
PRINCIPAL_INVESTIGATORAgni Pantou, MD

Centre of Human Reproduction, Genesis Athens Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 9, 2026